"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Descriptor ID |
D019380
|
MeSH Number(s) |
D27.505.954.122.388.077.088
|
Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1998 | 1 | 0 | 1 |
1999 | 2 | 3 | 5 |
2000 | 4 | 2 | 6 |
2001 | 3 | 0 | 3 |
2002 | 2 | 5 | 7 |
2003 | 4 | 4 | 8 |
2004 | 6 | 4 | 10 |
2005 | 1 | 4 | 5 |
2006 | 1 | 1 | 2 |
2007 | 9 | 4 | 13 |
2008 | 7 | 2 | 9 |
2009 | 3 | 4 | 7 |
2010 | 6 | 9 | 15 |
2011 | 6 | 1 | 7 |
2012 | 10 | 4 | 14 |
2013 | 13 | 7 | 20 |
2014 | 7 | 4 | 11 |
2015 | 5 | 4 | 9 |
2016 | 8 | 5 | 13 |
2017 | 10 | 5 | 15 |
2018 | 10 | 5 | 15 |
2019 | 3 | 2 | 5 |
2020 | 12 | 3 | 15 |
2021 | 7 | 2 | 9 |
2022 | 5 | 0 | 5 |
2023 | 6 | 0 | 6 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. J Antimicrob Chemother. 2024 Feb 01; 79(2):370-374.
-
Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature. Curr HIV/AIDS Rep. 2024 Feb; 21(1):1-10.
-
Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania. PLoS One. 2024; 19(1):e0292424.
-
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques. J Control Release. 2024 02; 366:18-27.
-
Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates. Sci Transl Med. 2023 06 28; 15(702):eadg2887.
-
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates. J Control Release. 2023 06; 358:116-127.
-
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Antimicrob Agents Chemother. 2023 04 18; 67(4):e0005323.
-
Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023 Jul 01; 42(7):576-581.
-
MyTPill: study protocol for a cross-over randomised controlled trial comparing novel strategies to monitor antiretroviral adherence among HIV+ prescription opioid users. BMJ Open. 2023 01 10; 13(1):e062805.
-
Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis. 2023 01 06; 76(1):10-17.